BetterLife Pharma (BETRF) Net Income towards Common Stockholders (2011 - 2026)

BetterLife Pharma's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$444456.7 for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 205.46% year-over-year to -$444456.7; the TTM figure through Apr 2026 stood at -$956844.0 (up 24.07% YoY), while the FY2026 annual figure was -$1.1 million, up 56.54% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at -$444456.7, down from -$366884.6 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $441202.5 in Q4 2024, with the low at -$3.5 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$741047.8 (2023), against an average of -$1.0 million.
• The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders jumped 379.9% in 2024, then plunged 205.46% in 2026.
• BetterLife Pharma's Net Income towards Common Stockholders stood at -$3.5 million in 2022, then surged by 95.53% to -$157629.0 in 2023, then surged by 379.9% to $441202.5 in 2024, then sank by 183.16% to -$366884.6 in 2025, then decreased by 21.14% to -$444456.7 in 2026.
• Business Quant data shows BETRF's Net Income towards Common Stockholders at -$444456.7 in Q2 2026, -$366884.6 in Q3 2025, and -$145502.8 in Q2 2025.